Figure 3.
Demonstration of the clinical utility of PIUKALL. (A) Visualization of 4 example patients on a pseudonomogram. The precise thresholds for defining each risk group were as follows: LR, ≤ −1.894893; SR, ≤ −1.279577; IR, ≤ −0.0856656; and HR, > −0.0856656. Table shows details of how the index was calculated for each patient. (B) Number of cases and event-free survival (EFS) rate, RR, and OS rate at 5 years for the 4 risk groups in both the discovery and validation cohorts. (C-E) Kaplan-Meier plots of EFS (C), RR (D), and OS (E). ln, natural log.

Demonstration of the clinical utility of PIUKALL. (A) Visualization of 4 example patients on a pseudonomogram. The precise thresholds for defining each risk group were as follows: LR, ≤ −1.894893; SR, ≤ −1.279577; IR, ≤ −0.0856656; and HR, > −0.0856656. Table shows details of how the index was calculated for each patient. (B) Number of cases and event-free survival (EFS) rate, RR, and OS rate at 5 years for the 4 risk groups in both the discovery and validation cohorts. (C-E) Kaplan-Meier plots of EFS (C), RR (D), and OS (E). ln, natural log.

Close Modal

or Create an Account

Close Modal
Close Modal